Navigation Links
Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes
Date:8/29/2008


Four-month study detailing effects of treatment of HIV-positive

individuals with American Biotech Labs (ABL) ASAP 10 treatment indicates

significant improvement in the condition of the subjects after treatment;

in-vitro laboratory work shows that ABL nanosilver particles can block

entry of the virus into cells, "eventually destroying the virus"

ALPINE, UT, Aug. 29 /PRNewswire-FirstCall/ - American Biotech Labs, developer of a new class of products based on the company's patented nano-catalytic SilverSol Technology(TM), today announced that a preliminary study of the effect of the company's ASAP 10 treatment on HIV-positive individuals has been published in the first issue of the Journal of the Science of Healing Outcomes (JSHO; http://www.thejsho.com/pdf/Effect.pdf). JSHO is a scholarly health journal that publishes compelling new medical research data and reports.

The study was conducted over four months with seven HIV-positive patients, each of whom was administered 15 ml of ABL ASAP 10 ppm (parts per million) four times daily. As a result of the ABL treatment, "Clinically, (the patients) were 100 percent fit and were feeling much better after the treatment period," said Dr. B.M. Hegde, world-renowned cardiologist and editor of JSHO.

During the course of the therapy, the patients experienced an average body weight gain of eight kilograms (17.6 pounds) and an average T-lymphocyte count increase of 180 per micro-liter (39.52 percent).

One of the study's most significant findings, said Hegde, was the effect of ABL ASAP on HIV, the AIDS-causing virus. "Our recent laboratory work of the effect of nano silver in vitro on the... virus did show that the nanosilver particles could bind to (HIV) and could potentially block the viral entry into cells, eventually destroying the virus."

Hegde added, "Now that we have the laboratory results of the drug's efficacy and safety, we are planning a large scale controlled study of the application to HIV positive individuals in the near future."

About American Biotech Labs

American Biotech Labs (ABL; http://www.AmericanBiotechLabs.com), founded in 1998, utilizes patented processes and SilverSol Technology(TM) to create singularly powerful and effective nano-catalytic silver products. In extensive testing performed by a variety of respected laboratories and researchers, ABL's silver hydrosol has consistently demonstrated the ability, without any known toxic side effects, to destroy a wide range of bacteria, viruses, yeast, and molds. ABL products have been approved by the U.S. EPA as a disinfectant for dental water lines, and as a surface disinfectant for bacteria, yeast and mold in hospital, residential, commercial and industrial settings. The company's products are sold worldwide at health food stores and by medical professionals under the Silver Biotics(R) and ASAP Solution(R) brands and through a variety of private labels.


'/>"/>
SOURCE Clifton Mining Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
3. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
4. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
5. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
6. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
7. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
8. Symmetry Medical Reports Preliminary Third Quarter Revenue
9. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
10. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
11. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... Research and Markets has announced the addition of the ... The global biomarkers market has ... The market is expected to grow at a five-year compound annual ... $50.6 billion in 2015 to $96.6 billion in 2020. ... to 2020) are discussed. As well, new products approved in 2013 ...
(Date:6/22/2016)... LOS ANGELES , June 22, 2016   ... an SNNLive Video Interview with Dr. Nader Pourhassan ... a biotechnology company focused on the clinical development and ... and prevention of HIV infection, according to the company,s ... was recorded on Tuesday, June 7 th , 2016, ...
(Date:6/22/2016)... DIEGO , June 22, 2016   ViaCyte, ... first pluripotent stem cell-derived islet replacement therapy for the ... presentations at ISSCR 2016 Annual Meeting.  ISSCR 2016, the ... to 25th at Moscone West in San Francisco.  ... of the presentations are as follows:Event: , Focus Session: ...
(Date:6/22/2016)... (PRWEB) , ... June 22, 2016 , ... ... at placing a spotlight on immigrant achievements and contributions to North Texas and ... most important contributors from the immigrant community to the civic and economic vitality ...
Breaking Biology Technology:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
Breaking Biology News(10 mins):